Key result
DOACs and warfarin show similar LAA thrombus rates in patients with NVAF.
Why the study?
Does DOAC compared to warfarin reduce the prevalence of LAA thrombi in Japanese NVAF patients undergoing preprocedural TEE?
Observational
Does DOAC compared to warfarin reduce the prevalence of LAA thrombi in Japanese NVAF patients undergoing preprocedural TEE?
LAA thrombi are present in 2.7% of Japanese NVAF patients on anticoagulation prior to procedures, with similar rates between DOACs and warfarin.
Answers are grounded in this paper and cite their sources.
Similar LAA thrombus rates do not guide anticoagulation choice; leaves open randomized TEE confirmation in Japanese NVAF.
BACKGROUND: Atrial fibrillation (AF) is a common cardiac arrhythmia, associated with increased cardiovascular morbidity and mortality including thromboembolic events. The aims of this study were to assess the prevalence of left atrial appendage (LAA) thrombi in Japanese non-valvular atrial fibrillation (NVAF) patients undergoing preprocedural transesophageal echocardiography (TEE) during anticoagulation therapy, and to compare the efficacy of warfarin and direct oral anticoagulants (DOAC). METHODS AND On multivariate analysis, BNP ≥173 pg/mL remained the only independent predictor of LAA thrombi. CONCLUSIONS: LAA thrombi were found in 2.7% of Japanese NVAF patients scheduled for procedures despite ongoing oral anticoagulation therapy. Incidence of thrombi was similar for patients on DOAC and on warfarin.
No takes yet. Share an insight, caveat, or question.
Kawabata et al. (2017) conducted an observational in Non-valvular atrial fibrillation. Direct oral anticoagulants (DOAC) vs. Warfarin was evaluated on Prevalence of left atrial appendage (LAA) thrombi. Direct oral anticoagulants and warfarin showed a similar incidence of left atrial appendage thrombi in Japanese patients with non-valvular atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: